The laboratory diagnosis of genital human papillomavirus infections

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 16, Issue 2, 2005, Pages 83-91

  Coutlée, François ^a,b,d   Rouleau, Danielle ^a   Ferenczy, Alex ^b   Franco, Eduardo ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NOTRE DAME HOSPITAL   (Canada)

Author keywords

Cancer; HPV; PCR; Screening; STI

Indexed keywords

COLPOSCOPY; CONSENSUS SEQUENCE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GENITAL TRACT CANCER; HIGH RISK POPULATION; HUMAN; LABORATORY DIAGNOSIS; REVIEW; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS LOAD; WART VIRUS;

EID: 23244434174     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/798710     Document Type: Review

References (44)

1. Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 2002;3:11-6.
2. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: Epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001;164:1017-25.
3. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
4. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
5. Sawaya GF, Brown AD, Washington AE, Garber AM. Clinical practice. Current approaches to cervical-cancer screening. N Engl J Med 2001;344:1603-7.
6. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
7. Coutlée F, Mayrand MH, Provencher D, Franco E. The future of HPV testing in clinical laboratories and applied virology research. Clin Diagn Virol 1997;8:123-41.
8. Peyton CL, Schiffman M, Lorincz AT, et al. Comparison of PCR-and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998;36:3248-54.
9. van Doorn LJ, Quint W, Kleter B, et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol 2002;40:979-83.
10. The Atypical Squamous Cells of Undetermined Significance/ Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
11. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-6.
12. Sellors JW, Lorincz AT, Mahony JB, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 2000;163:513-8.
13. Bauer HM, Greer CE, Manos MM. Determination of genital human papillomavirus infection by consensus polymerase chain reaction amplification. In: Herrington CS, McGee JOD, eds. Diagnostic Molecular Pathology: A Practical Approach, 1st edn. Oxford: Oxford University Press, 1992:131-52.
14. Feoli-Fonseca JC, Oligny LL, Brochu P, Simard P, Falconi S, Yotov WV. Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR-direct sequencing approach. J Med Virol 2001;63:284-92.
15. Kiviat NB. Human papillomavirus. In: Murray PR, Baron EJ, Pfaller MA, Jorgensen JH, Yolken RH, eds. Manual of Clinical Microbiology, 7th edn. Washington: American Society Microbiology, 1999:1070-9.
16. de Sanjose S, Palefsky J. Cervical and anal HPV infections in HIV positive women and men. Virus Res 2002;89:201-11.
17. Ferenczy A, Franco E. Cervical-cancer screening beyond the year 2000. Lancet Oncol 2001;2:27-32.
18. Lorincz AT. Molecular methods for the detection of human papillomavirus infection. In: Crum CP, Lorincz AT, eds. Human Papillomavirus. New York: Saunders, 1996:707-31.
19. Lorincz A, Anthony J. Advances in HPV detection by hybrid capture. Papillomavirus Rep 2001;12:145-54.
20. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
21. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
22. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: Comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997;35:1304-10.
23. Peitsaro P, Johansson B, Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002;40:886-91.
24. Swan DC, Tucker RA, Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999;37:1030-4.
25. Giannoudis A, Herrington CS. Human papillomavirus variants and squamous neoplasia of the cervix. J Pathol 2001;193:295-302.
26. Mayrand MH, Coutlee F, Hankins C, et al. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J Clin Microbiol 2000;38:3388-93.
27. Villa LL, Sichero L, Rahal P, et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000;81:2959-68.
28. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999;9:423-30.
29. Schiffman MH, Kiviat NB, Burk RD, et al. Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture. J Clin Microbiol 1995;33:545-50.
30. Kornegay JR, Roger M, Davies PO, et al. International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: Evaluation of accuracy and intralaboratory and interlaboratory agreement. J Clin Microbiol 2003;41:1080-6.
31. Coutlée F, de Ladurantaye M, Tremblay C, Vincelette J, Labrecque L, Roger M. An important proportion of genital samples submitted for Chlamydia trachomatis detection by PCR contain small amounts of cellular DNA as measured by beta-globin gene amplification. J Clin Microbiol 2000;38:2512-5.
32. van Duin M, Snidjers PJ, Schrijnemakers HF, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance. Int J Cancer 2002;98:590-5.
33. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818-25.
34. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945-51.
35. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: A study of 7932 women. Br J Cancer 2001;84:1616-23.
36. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness. JAMA 2001;285:3107-15.
37. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:485-90.
38. Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003;168:421-5.
39. Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 2000;163:503-8.
40. Solomon D, Schiffman M, Tarone R; ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
41. Sherman ME, Schiffman M, Cox JT; Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Effects of age and human papilloma viral load on colposcopy triage: Data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2002;94:102-7.
42. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-10.
43. Denise Zielinski G, Snijders PJ, Rozendaal L, et al. High-risk HPV testing in women with borderline and mild dyskaryosis: Long-term follow-up data and clinical relevance. J Pathol 2001;195:300-6.
44. Lytwyn A, Sellors JW, Mahony JB, et al. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: A randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group. CMAJ 2000;163:701-7.